Repligen Corporation (RGEN) Stock Competitors & Peer Comparison
See (RGEN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RGEN | $126.55 | +3.96% | 7.1B | 139.07 | $0.91 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.36% |
| BDX | $149.56 | +2.71% | 54.2B | 26.10 | $5.73 | +2.36% |
| ALC | $66.58 | +3.67% | 32.5B | 39.87 | $1.67 | +0.54% |
| MDLN | $34.45 | -0.06% | 29.1B | 30.22 | $1.14 | N/A |
| WST | $317.32 | +0.32% | 22.4B | 42.37 | $7.49 | +0.28% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.36% |
| COO | $62.02 | +2.78% | 12.1B | 30.89 | $2.01 | N/A |
| BAX | $19.35 | +4.37% | 10B | -10.13 | -$1.91 | +1.04% |
Stock Comparison
RGEN vs BDXA Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, RGEN is priced at $126.55, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas BDXA's P/E ratio is 21.44. In terms of profitability, RGEN's ROE is +0.02%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, RGEN is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check BDXA's competition here
RGEN vs BDX Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, BDX has a market cap of 54.2B. Regarding current trading prices, RGEN is priced at $126.55, while BDX trades at $149.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas BDX's P/E ratio is 26.10. In terms of profitability, RGEN's ROE is +0.02%, compared to BDX's ROE of +0.05%. Regarding short-term risk, RGEN is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check BDX's competition here
RGEN vs ALC Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ALC has a market cap of 32.5B. Regarding current trading prices, RGEN is priced at $126.55, while ALC trades at $66.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ALC's P/E ratio is 39.87. In terms of profitability, RGEN's ROE is +0.02%, compared to ALC's ROE of +0.04%. Regarding short-term risk, RGEN is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check ALC's competition here
RGEN vs MDLN Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, MDLN has a market cap of 29.1B. Regarding current trading prices, RGEN is priced at $126.55, while MDLN trades at $34.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas MDLN's P/E ratio is 30.22. In terms of profitability, RGEN's ROE is +0.02%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, RGEN is more volatile compared to MDLN. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check MDLN's competition here
RGEN vs WST Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, WST has a market cap of 22.4B. Regarding current trading prices, RGEN is priced at $126.55, while WST trades at $317.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas WST's P/E ratio is 42.37. In terms of profitability, RGEN's ROE is +0.02%, compared to WST's ROE of +0.18%. Regarding short-term risk, RGEN is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check WST's competition here
RGEN vs HOLX Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, RGEN is priced at $126.55, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas HOLX's P/E ratio is 31.54. In terms of profitability, RGEN's ROE is +0.02%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, RGEN is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check HOLX's competition here
RGEN vs BDXB Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, RGEN is priced at $126.55, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas BDXB's P/E ratio is 7.60. In terms of profitability, RGEN's ROE is +0.02%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, RGEN is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check BDXB's competition here
RGEN vs COO Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, COO has a market cap of 12.1B. Regarding current trading prices, RGEN is priced at $126.55, while COO trades at $62.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas COO's P/E ratio is 30.89. In terms of profitability, RGEN's ROE is +0.02%, compared to COO's ROE of +0.05%. Regarding short-term risk, RGEN is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check COO's competition here
RGEN vs BAX Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, BAX has a market cap of 10B. Regarding current trading prices, RGEN is priced at $126.55, while BAX trades at $19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas BAX's P/E ratio is -10.13. In terms of profitability, RGEN's ROE is +0.02%, compared to BAX's ROE of -0.16%. Regarding short-term risk, RGEN is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check BAX's competition here
RGEN vs ATR Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ATR has a market cap of 7.2B. Regarding current trading prices, RGEN is priced at $126.55, while ATR trades at $112.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ATR's P/E ratio is 19.28. In terms of profitability, RGEN's ROE is +0.02%, compared to ATR's ROE of +0.14%. Regarding short-term risk, RGEN is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check ATR's competition here
RGEN vs AVTR Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, AVTR has a market cap of 6.5B. Regarding current trading prices, RGEN is priced at $126.55, while AVTR trades at $9.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas AVTR's P/E ratio is -11.77. In terms of profitability, RGEN's ROE is +0.02%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, RGEN is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check AVTR's competition here
RGEN vs TFX Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, TFX has a market cap of 5.9B. Regarding current trading prices, RGEN is priced at $126.55, while TFX trades at $132.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas TFX's P/E ratio is 2203.17. In terms of profitability, RGEN's ROE is +0.02%, compared to TFX's ROE of -0.28%. Regarding short-term risk, RGEN is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check TFX's competition here
RGEN vs BLCO Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, BLCO has a market cap of 5.5B. Regarding current trading prices, RGEN is priced at $126.55, while BLCO trades at $15.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas BLCO's P/E ratio is -24.77. In terms of profitability, RGEN's ROE is +0.02%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, RGEN is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check BLCO's competition here
RGEN vs STVN Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, STVN has a market cap of 5.1B. Regarding current trading prices, RGEN is priced at $126.55, while STVN trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas STVN's P/E ratio is 31.44. In terms of profitability, RGEN's ROE is +0.02%, compared to STVN's ROE of +0.10%. Regarding short-term risk, RGEN is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check STVN's competition here
RGEN vs MMSI Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, MMSI has a market cap of 3.8B. Regarding current trading prices, RGEN is priced at $126.55, while MMSI trades at $63.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas MMSI's P/E ratio is 27.19. In terms of profitability, RGEN's ROE is +0.02%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, RGEN is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check MMSI's competition here
RGEN vs ICUI Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ICUI has a market cap of 3.4B. Regarding current trading prices, RGEN is priced at $126.55, while ICUI trades at $134.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ICUI's P/E ratio is 72.54. In terms of profitability, RGEN's ROE is +0.02%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, RGEN is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check ICUI's competition here
RGEN vs HAE Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, HAE has a market cap of 3.2B. Regarding current trading prices, RGEN is priced at $126.55, while HAE trades at $69.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas HAE's P/E ratio is 34.08. In terms of profitability, RGEN's ROE is +0.02%, compared to HAE's ROE of +0.11%. Regarding short-term risk, RGEN is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check HAE's competition here
RGEN vs WRBY Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, WRBY has a market cap of 3B. Regarding current trading prices, RGEN is priced at $126.55, while WRBY trades at $24.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas WRBY's P/E ratio is 2412.00. In terms of profitability, RGEN's ROE is +0.02%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, RGEN is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check WRBY's competition here
RGEN vs LMAT Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, LMAT has a market cap of 2.1B. Regarding current trading prices, RGEN is priced at $126.55, while LMAT trades at $93.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas LMAT's P/E ratio is 34.40. In terms of profitability, RGEN's ROE is +0.02%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, RGEN is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check LMAT's competition here
RGEN vs NVCR Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, RGEN is priced at $126.55, while NVCR trades at $17.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas NVCR's P/E ratio is -11.76. In terms of profitability, RGEN's ROE is +0.02%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, RGEN is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check NVCR's competition here
RGEN vs XRAY Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, RGEN is priced at $126.55, while XRAY trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas XRAY's P/E ratio is -3.14. In terms of profitability, RGEN's ROE is +0.02%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, RGEN is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check XRAY's competition here
RGEN vs PLSE Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, PLSE has a market cap of 1.9B. Regarding current trading prices, RGEN is priced at $126.55, while PLSE trades at $26.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas PLSE's P/E ratio is -24.49. In terms of profitability, RGEN's ROE is +0.02%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, RGEN is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check PLSE's competition here
RGEN vs STAA Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, STAA has a market cap of 1.5B. Regarding current trading prices, RGEN is priced at $126.55, while STAA trades at $29.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas STAA's P/E ratio is -71.10. In terms of profitability, RGEN's ROE is +0.02%, compared to STAA's ROE of -0.06%. Regarding short-term risk, RGEN is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check STAA's competition here
RGEN vs ATRC Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ATRC has a market cap of 1.4B. Regarding current trading prices, RGEN is priced at $126.55, while ATRC trades at $27.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ATRC's P/E ratio is -272.70. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, RGEN is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check ATRC's competition here
RGEN vs BLFS Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, BLFS has a market cap of 1.3B. Regarding current trading prices, RGEN is priced at $126.55, while BLFS trades at $27.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas BLFS's P/E ratio is -112.87. In terms of profitability, RGEN's ROE is +0.02%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, RGEN is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check BLFS's competition here
RGEN vs KMTS Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, RGEN is priced at $126.55, while KMTS trades at $20.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas KMTS's P/E ratio is -3.75. In terms of profitability, RGEN's ROE is +0.02%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, RGEN is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check KMTS's competition here
RGEN vs NNNN Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, NNNN has a market cap of 1.2B. Regarding current trading prices, RGEN is priced at $126.55, while NNNN trades at $27.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas NNNN's P/E ratio is 180.87. In terms of profitability, RGEN's ROE is +0.02%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, RGEN is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check NNNN's competition here
RGEN vs AZTA Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, AZTA has a market cap of 1.1B. Regarding current trading prices, RGEN is priced at $126.55, while AZTA trades at $22.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas AZTA's P/E ratio is -9.48. In terms of profitability, RGEN's ROE is +0.02%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, RGEN is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check AZTA's competition here
RGEN vs QDEL Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, QDEL has a market cap of 1B. Regarding current trading prices, RGEN is priced at $126.55, while QDEL trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas QDEL's P/E ratio is -0.86. In terms of profitability, RGEN's ROE is +0.02%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, RGEN is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check QDEL's competition here
RGEN vs ATRI Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, RGEN is priced at $126.55, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ATRI's P/E ratio is 64.50. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, RGEN is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check ATRI's competition here
RGEN vs ANGO Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ANGO has a market cap of 497.1M. Regarding current trading prices, RGEN is priced at $126.55, while ANGO trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ANGO's P/E ratio is -15.83. In terms of profitability, RGEN's ROE is +0.02%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, RGEN is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check ANGO's competition here
RGEN vs OSUR Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, OSUR has a market cap of 287.1M. Regarding current trading prices, RGEN is priced at $126.55, while OSUR trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas OSUR's P/E ratio is -3.97. In terms of profitability, RGEN's ROE is +0.02%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, RGEN is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check OSUR's competition here
RGEN vs UTMD Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, UTMD has a market cap of 216.5M. Regarding current trading prices, RGEN is priced at $126.55, while UTMD trades at $67.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas UTMD's P/E ratio is 20.12. In terms of profitability, RGEN's ROE is +0.02%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, RGEN is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check UTMD's competition here
RGEN vs PDEX Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, PDEX has a market cap of 213.9M. Regarding current trading prices, RGEN is priced at $126.55, while PDEX trades at $67.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas PDEX's P/E ratio is 18.46. In terms of profitability, RGEN's ROE is +0.02%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, RGEN is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check PDEX's competition here
RGEN vs SMTI Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, SMTI has a market cap of 202.7M. Regarding current trading prices, RGEN is priced at $126.55, while SMTI trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas SMTI's P/E ratio is 368.67. In terms of profitability, RGEN's ROE is +0.02%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, RGEN is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check SMTI's competition here
RGEN vs KRMD Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, KRMD has a market cap of 190.2M. Regarding current trading prices, RGEN is priced at $126.55, while KRMD trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas KRMD's P/E ratio is -82.80. In terms of profitability, RGEN's ROE is +0.02%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, RGEN is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check KRMD's competition here
RGEN vs INFU Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, INFU has a market cap of 184.9M. Regarding current trading prices, RGEN is priced at $126.55, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas INFU's P/E ratio is 24.76. In terms of profitability, RGEN's ROE is +0.02%, compared to INFU's ROE of +0.14%. Regarding short-term risk, RGEN is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check INFU's competition here
RGEN vs STXS Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, STXS has a market cap of 182.8M. Regarding current trading prices, RGEN is priced at $126.55, while STXS trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas STXS's P/E ratio is -7.79. In terms of profitability, RGEN's ROE is +0.02%, compared to STXS's ROE of -1.53%. Regarding short-term risk, RGEN is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check STXS's competition here
RGEN vs NYXH Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, NYXH has a market cap of 108.9M. Regarding current trading prices, RGEN is priced at $126.55, while NYXH trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas NYXH's P/E ratio is -1.17. In terms of profitability, RGEN's ROE is +0.02%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, RGEN is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check NYXH's competition here
RGEN vs MBOT Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, MBOT has a market cap of 89.3M. Regarding current trading prices, RGEN is priced at $126.55, while MBOT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas MBOT's P/E ratio is -7.54. In terms of profitability, RGEN's ROE is +0.02%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, RGEN is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check MBOT's competition here
RGEN vs AKYA Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, RGEN is priced at $126.55, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas AKYA's P/E ratio is -1.34. In terms of profitability, RGEN's ROE is +0.02%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, RGEN is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check AKYA's competition here
RGEN vs STSS Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, STSS has a market cap of 61.4M. Regarding current trading prices, RGEN is priced at $126.55, while STSS trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas STSS's P/E ratio is -0.02. In terms of profitability, RGEN's ROE is +0.02%, compared to STSS's ROE of -1.66%. Regarding short-term risk, RGEN is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check STSS's competition here
RGEN vs DXR Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, DXR has a market cap of 56.2M. Regarding current trading prices, RGEN is priced at $126.55, while DXR trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas DXR's P/E ratio is 6.80. In terms of profitability, RGEN's ROE is +0.02%, compared to DXR's ROE of +0.22%. Regarding short-term risk, RGEN is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check DXR's competition here
RGEN vs ZTEK Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ZTEK has a market cap of 55.6M. Regarding current trading prices, RGEN is priced at $126.55, while ZTEK trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ZTEK's P/E ratio is -8.61. In terms of profitability, RGEN's ROE is +0.02%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, RGEN is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check ZTEK's competition here
RGEN vs OMIC Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, RGEN is priced at $126.55, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas OMIC's P/E ratio is -0.58. In terms of profitability, RGEN's ROE is +0.02%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, RGEN is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check OMIC's competition here
RGEN vs IGAP Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, RGEN is priced at $126.55, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas IGAP's P/E ratio is -10.52. In terms of profitability, RGEN's ROE is +0.02%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, RGEN is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check IGAP's competition here
RGEN vs POCI Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, POCI has a market cap of 42.7M. Regarding current trading prices, RGEN is priced at $126.55, while POCI trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas POCI's P/E ratio is -8.64. In terms of profitability, RGEN's ROE is +0.02%, compared to POCI's ROE of -0.37%. Regarding short-term risk, RGEN is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check POCI's competition here
RGEN vs NEPH Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, NEPH has a market cap of 38.2M. Regarding current trading prices, RGEN is priced at $126.55, while NEPH trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas NEPH's P/E ratio is 50.29. In terms of profitability, RGEN's ROE is +0.02%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, RGEN is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check NEPH's competition here
RGEN vs MLSS Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, MLSS has a market cap of 38.1M. Regarding current trading prices, RGEN is priced at $126.55, while MLSS trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas MLSS's P/E ratio is -7.22. In terms of profitability, RGEN's ROE is +0.02%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, RGEN is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check MLSS's competition here
RGEN vs SDC Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, RGEN is priced at $126.55, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas SDC's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to SDC's ROE of -1.96%. Regarding short-term risk, RGEN is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check SDC's competition here
RGEN vs HBIO Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, HBIO has a market cap of 29M. Regarding current trading prices, RGEN is priced at $126.55, while HBIO trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas HBIO's P/E ratio is -2.99. In terms of profitability, RGEN's ROE is +0.02%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, RGEN is more volatile compared to HBIO. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check HBIO's competition here
RGEN vs EKSO Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, EKSO has a market cap of 28.6M. Regarding current trading prices, RGEN is priced at $126.55, while EKSO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas EKSO's P/E ratio is -2.31. In terms of profitability, RGEN's ROE is +0.02%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, RGEN is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check EKSO's competition here
RGEN vs IVC Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, RGEN is priced at $126.55, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas IVC's P/E ratio is -0.79. In terms of profitability, RGEN's ROE is +0.02%, compared to IVC's ROE of -0.46%. Regarding short-term risk, RGEN is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check IVC's competition here
RGEN vs ZJYL Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ZJYL has a market cap of 21.1M. Regarding current trading prices, RGEN is priced at $126.55, while ZJYL trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ZJYL's P/E ratio is 13.50. In terms of profitability, RGEN's ROE is +0.02%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, RGEN is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check ZJYL's competition here
RGEN vs RVP Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, RVP has a market cap of 19.5M. Regarding current trading prices, RGEN is priced at $126.55, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas RVP's P/E ratio is -2.95. In terms of profitability, RGEN's ROE is +0.02%, compared to RVP's ROE of -0.08%. Regarding short-term risk, RGEN is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check RVP's competition here
RGEN vs FEMY Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, FEMY has a market cap of 10.5M. Regarding current trading prices, RGEN is priced at $126.55, while FEMY trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas FEMY's P/E ratio is -1.49. In terms of profitability, RGEN's ROE is +0.02%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, RGEN is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check FEMY's competition here
RGEN vs RGNT Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, RGNT has a market cap of 6.8M. Regarding current trading prices, RGEN is priced at $126.55, while RGNT trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas RGNT's P/E ratio is -0.07. In terms of profitability, RGEN's ROE is +0.02%, compared to RGNT's ROE of N/A. Regarding short-term risk, RGEN is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check RGNT's competition here
RGEN vs NXGL Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, NXGL has a market cap of 5.4M. Regarding current trading prices, RGEN is priced at $126.55, while NXGL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas NXGL's P/E ratio is -1.47. In terms of profitability, RGEN's ROE is +0.02%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, RGEN is more volatile compared to NXGL. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check NXGL's competition here
RGEN vs NSTG Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, RGEN is priced at $126.55, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas NSTG's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, RGEN is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check NSTG's competition here
RGEN vs LUCY Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, LUCY has a market cap of 3.8M. Regarding current trading prices, RGEN is priced at $126.55, while LUCY trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas LUCY's P/E ratio is -0.61. In terms of profitability, RGEN's ROE is +0.02%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, RGEN is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check LUCY's competition here
RGEN vs POAI Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, RGEN is priced at $126.55, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas POAI's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to POAI's ROE of -107.05%. Regarding short-term risk, RGEN is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check POAI's competition here
RGEN vs NXGLW Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, NXGLW has a market cap of 2.9M. Regarding current trading prices, RGEN is priced at $126.55, while NXGLW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas NXGLW's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, RGEN is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check NXGLW's competition here
RGEN vs MHUA Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, RGEN is priced at $126.55, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas MHUA's P/E ratio is 0.25. In terms of profitability, RGEN's ROE is +0.02%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, RGEN is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check MHUA's competition here
RGEN vs GMVD Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, RGEN is priced at $126.55, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas GMVD's P/E ratio is -0.01. In terms of profitability, RGEN's ROE is +0.02%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, RGEN is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check GMVD's competition here
RGEN vs GMVDW Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, RGEN is priced at $126.55, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas GMVDW's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, RGEN is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check GMVDW's competition here
RGEN vs AVGR Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, RGEN is priced at $126.55, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas AVGR's P/E ratio is -0.05. In terms of profitability, RGEN's ROE is +0.02%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, RGEN is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check AVGR's competition here
RGEN vs STSSW Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, RGEN is priced at $126.55, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas STSSW's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to STSSW's ROE of +0.12%. Regarding short-term risk, RGEN is more volatile compared to STSSW. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check STSSW's competition here
RGEN vs GCTK Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, GCTK has a market cap of 383.5K. Regarding current trading prices, RGEN is priced at $126.55, while GCTK trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas GCTK's P/E ratio is 0.11. In terms of profitability, RGEN's ROE is +0.02%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, RGEN is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check GCTK's competition here
RGEN vs LUCYW Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, RGEN is priced at $126.55, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas LUCYW's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, RGEN is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check LUCYW's competition here
RGEN vs WOK Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, WOK has a market cap of 597. Regarding current trading prices, RGEN is priced at $126.55, while WOK trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas WOK's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to WOK's ROE of -0.07%. Regarding short-term risk, RGEN is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for RGEN.Check WOK's competition here
RGEN vs APR Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, APR has a market cap of 0. Regarding current trading prices, RGEN is priced at $126.55, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas APR's P/E ratio is 22.59. In terms of profitability, RGEN's ROE is +0.02%, compared to APR's ROE of +9.81%. Regarding short-term risk, RGEN is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check APR's competition here
RGEN vs IVTY Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, RGEN is priced at $126.55, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas IVTY's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, RGEN is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check IVTY's competition here
RGEN vs IIN Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, IIN has a market cap of 0. Regarding current trading prices, RGEN is priced at $126.55, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas IIN's P/E ratio is 226.45. In terms of profitability, RGEN's ROE is +0.02%, compared to IIN's ROE of -0.00%. Regarding short-term risk, RGEN is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check IIN's competition here
RGEN vs ATRS Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, RGEN is priced at $126.55, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ATRS's P/E ratio is 14.95. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, RGEN is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check ATRS's competition here
RGEN vs HRC Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, HRC has a market cap of 0. Regarding current trading prices, RGEN is priced at $126.55, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas HRC's P/E ratio is 41.92. In terms of profitability, RGEN's ROE is +0.02%, compared to HRC's ROE of +0.14%. Regarding short-term risk, RGEN is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check HRC's competition here
RGEN vs ARTC Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ARTC has a market cap of 0. Regarding current trading prices, RGEN is priced at $126.55, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ARTC's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to ARTC's ROE of N/A. Regarding short-term risk, RGEN is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check ARTC's competition here
RGEN vs ALOG Comparison June 2026
RGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 7.1B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, RGEN is priced at $126.55, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 139.07, whereas ALOG's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, RGEN is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for RGEN.Check ALOG's competition here